24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason , a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples.
Read more here.
The post [CytoReason in Share Talk] Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason appeared first on OurCrowd Blog.
